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Abstract
Aims: Leptin plays an important role in the pathogenesis of obesity and diabetes,
yet the regulatory mechanisms of this hormone have not been fully elucidated. In
this study, we aimed to clarify the roles of insulin and glucose in leptin secretion
and mRNA production using inhibitors of insulin signal transduction in adipocytes
cultured under glucose-free or normal conditions.
Methods: Differentiated 3T3-L1 adipocytes were stimulated with insulin in
combination with inhibitors for phosphoinositide 3-kinase (PI3K), Akt, and
phosphodiesterase 3B (PDE3B), as well as epinephrine and a cyclic AMP (cAMP)
analog under glucose-free or normal conditions. After 8 h of stimulation, leptin
protein levels in the media and leptin mRNA expression levels in the adipocytes
were measured.
Results: Insulin significantly increased the secretion and mRNA levels of leptin
under the depletion of glucose. Glucose augmented basal leptin secretion without
insulin, while glucose nullified insulin-induced leptin mRNA upregulation. The
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PI3K inhibitor BEZ-235, the Akt inhibitor MK-2206, and the PDE3B inhibitor
cilostazol attenuated the insulin stimulation of leptin secretion, but did not suppress
the insulin-induced leptin mRNA upregulation with glucose depletion. In contrast
to the glucose-free condition, insulin failed to upregulate leptin mRNA in the
presence of glucose. The cAMP analog dibutyryl cAMP and epinephrine decreased
both leptin secretion and mRNA regardless of glucose supplementation.
Conclusion: Insulin alone stimulates leptin secretion and elevates leptin mRNA
levels via cAMP under the lack of glucose metabolism, while glucose is a
significant and ambivalent effector on the insulin effects of leptin.
Keywords: Medicine, Endocrinology
1. Introduction
Leptin, a hormone secreted by mature adipocytes, plays an important role in the
pathogenesis of obesity and diabetes. Leptin suppress appetite, increases energy
consumption, and enhances insulin sensitivity via its receptors in the hypothalamus
[1, 2, 3].
The concentration of serum leptin has been reported to correlate with body fat
percentage [4], indicating that the total amount of adipocytes may be an important
determinant of leptin levels. On the contrary, multiple hormones and nutrients
affect leptin secretion [5, 6] and insulin is a well demonstrated secretagogue of
leptin both in vitro and in vivo [7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. Nevertheless,
the mechanisms of insulin action on leptin are still arguable.
The insulin stimulation of leptin has been attributed to accelerated glucose
metabolism rather than direct effects [12, 13, 14]. In contrast, multiple studies have
suggested that insulin-stimulated leptin secretion is not dependent on glucose [15,
16, 17]. Although the phosphoinositide 3-kinase (PI3K)- phosphodiesterase 3B
(PDE3B) pathway [7, 10] and cyclic AMP (cAMP) [7, 18, 19, 20] have been
reported to mediate the insulin stimulation of leptin, whether the insulin signal
contributes to leptin secretion via accelerated glucose metabolism or directly
affects it irrespective of glucose still needs to be clarified.
It is also debatable whether insulin signals and glucose catabolism enhance only
leptin secretion or also upregulate leptin synthesis. Insulin stimulation of leptin
levels has been associated with its secretion, yet reported observations are diverse
depending on experimental conditions [5]. Accelerated glucose metabolism may
also increase leptin mRNA levels or protein synthesis in adipocytes [14, 16, 21]
and inversely, deprivation of glucose may downregulate leptin mRNA levels [14],
although the effects may not be specific to glucose metabolism but simply be
attributed to energy status [22].
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To elucidate these issues, we examined the role of insulin on the secretion and the
mRNA levels of leptin in mature 3T3L1 adipocytes cultured under the depletion of
glucose and under normal conditions. Here we report that glucose is not essential
for insulin effects on leptin secretion and mRNA levels yet is a significant and
ambivalent factor of insulin effects.
2. Materials and methods
2.1. Cell culture
The 3T3-L1 pre-adipocytes were purchased from American Type Culture
Collection (Manassas, VA, USA). Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) containing 25 mM
glucose and 10% fetal bovine serum (FBS; Thermo Scientific, Waltham, MA,
USA), and penicillin and streptomycin (Sigma-Aldrich) at 37 °C in a humidified
5% CO2/95% air atmosphere. Two days after reaching full confluence, the pre-
adipocytes were differentiated into mature adipocytes by culturing with 10% FBS
supplemented DMEM containing 0.5 mM 3-isobutyl-1-methlyxanthine (IBMX,
Sigma-Aldrich), 0.25 μM dexamethasone (Sigma-Aldrich), and 5 μg/ml insulin
(Sigma-Aldrich) for two days, and subsequently with medium containing 5 μg/ml
insulin for two days. The 3T3-L1 adipocytes were used for experiments at day 10
of differentiation.
The prepared adipocytes were incubated in serum-free DMEM containing 3% BSA
with glucose at concentrations of 0, 5.5 mM, or 25 mM, and in the presence or
absence of insulin (0.5 μM), the PI3K inhibitor BEZ-235 (0.1–10 μM, Selleck,
Houston, TX, USA), the serine/threonine protein kinase (Akt) inhibitor MK-2206
(0.1–10 μM, Cayman Chemicals, Ann Arbor, MI, USA), the phosphodiesterase 3B
(PDE3B) inhibitor cilostazol (0.1–1 μM, Cayman Chemicals), a membrane-
permeable cAMP analog dibutyryl cAMP (100–400 μM, R&D Systems,
Minneapolis, MN, USA), epinephrine (0.1–10 μM, Sigma-Aldrich), an alpha-1
adrenergic antagonist prazosin (10 μM, Sigma-Aldrich), and a nonselective beta-
blocking agent propranolol (10 μM, Sigma-Aldrich). The doses of each agent were
selected in reference to previous studies [23, 24, 25, 26]. The incubation time was
determined as 8 h, because time course experiment revealed that both leptin mRNA
and secretion were significantly increased with insulin stimulation at 8 h, and
further incubation under glucose-free and serum-free condition may damage cell
functions. After incubation, cell culture media and cells were collected and used to
measure leptin protein concentrations and mRNA levels.
2.2. Quantification of leptin
Leptin levels in media samples were measured using a sandwich enzyme-linked
immunosorbent assay kit (R&D Systems) as per the manufacturer’s instructions,
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except that we used twice volume of samples. Intra-assay and inter-assay CV
values are 4.3% and 7.6%, respectively. The sensitivity we validated was 7.8 pg/ml.
2.3. Quantitative real-time PCR
Total RNA was extracted from 3T3-L1 adipocytes using the High Pure RNATM kit
(Roche, Indianapolis, IN, USA) and reverse transcribed into cDNA by a
PrimeScriptTM RT reagent kit (Takara Bio, Kusatsu, Japan) under the conditions
recommended by the manufacturer. Real-time PCR analysis was undertaken using
SYBR Premix Ex TaqTM (Takara Bio) and a Step One PlusTM System (Applied
Biosystems, Foster City, CA, USA). Amplification consisted of an initial step (95
°C for 30 s), 40 cycles of denaturation for 5 s at 95 °C and annealing for 30 s at 60
°C. The measurement was duplicated and the expression level of leptin mRNA was
normalized relative to the level of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
The mouse leptin primers used were 5′- caggatcaatgacatttcacaca-3′ and 5′-
gctggtgaggacctgttgat-3′ and those for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were 5′-tccactcatggcaaattcaa-3′ and 5′-tttgatgttagtggggtctcg-3′. The
mRNA expression levels of leptin were normalized relative to GAPDH mRNA
levels.
2.4. 3-(4,5-Dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) assay
To assess cytotoxicity by inhibitors, cells were cultured with each agent for 24 h,
and 20 μL of CellTiter 96 Aqueous One Solution ReagentTM (Promega, Madison,
WI) was added to each well. The plate was incubated for 1 h, followed by the
reading of absorbance at 490 nm.
2.5. Statistical analyses
All statistical analyses were performed with the Prism 5.02 program (GraphPad
Software, San Diego, CA, USA). For comparison among groups, the Tukey-
Kramer method and one-way analysis of variance (ANOVA) were applied. P
values less than 0.05 were considered statistically significant.
3. Results
3.1. Effect of insulin and glucose on the secretion and mRNA
expression of leptin in 3T3-L1 adipocytes
We first examined the effects of insulin on leptin secretion and mRNA expression
in the absence or presence of glucose in 3T3-L1 adipocytes. Insulin significantly
increased both secretion and mRNA expression of leptin under the depletion of
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ambient glucose (Fig. 1A and B). Glucose augmented basal leptin secretion
without insulin stimulation in a concentration-dependent manner, whereas glucose
did not amplify the insulin effects on leptin secretion. Neither 5.5 mM nor 25 mM
glucose increased mRNA expression of leptin, and the insulin stimulation on leptin
mRNA seen in glucose-free media was cancelled in the presence of glucose
(Fig. 1B).
3.2. Regulation of leptin secretion and mRNA expression by
insulin via the PI3K-AKT pathway with the depletion of glucose
We then examined the effects of insulin signal inhibitors on leptin secretion and
mRNA levels in 3T3-L1 adipocytes deprived of glucose. The PI3K inhibitor BEZ-
235 attenuated the insulin stimulation of leptin secretion in a dose-dependent
manner (Fig. 2A). In contrast, BEZ-235 did not suppress the upregulation of leptin
mRNA by insulin (Fig. 2B). Another PI3K inhibitor, wortomannin, also inhibited
the insulin-induced leptin secretion (Fig. 2C). The effects of the Akt inhibitor MK-
2206 were similar. MK-2206 dose-dependently inhibited insulin-induced leptin
secretion but not its mRNA expression with glucose depletion (Fig. 2D and E).
Neither BEZ-235 nor MK-2206 affected cell viability assessed by MTS assay
(Fig. 2F).
3.3. Effects of PDE3B inhibition and cAMP on leptin secretion
and mRNA expression
PDE3B, an enzyme catalyzing the conversion of cAMP to AMP, is expressed in
adipocytes [7] and located downstream of Akt signaling. The PDE3B inhibitor
cilostazol suppressed insulin stimulated leptin secretion in a dose-dependent
manner, while it showed no effect on leptin mRNA levels under the lack of glucose
[(Fig._1)TD$FIG]
Fig. 1. Effects of glucose concentration and insulin on the secretion (A) and mRNA levels (B) of leptin
in 3T3-L1 adipocytes. 3T3-L1 adipocytes were incubated for 8 h in DMEM containing 0, 5.5, or 25 mM
glucose in the presence or absence of 0.5 μM insulin. *p< 0.05, **p< 0.01, and ***p < 0.001. n.s., not
significant. Data are expressed as means ± SE.
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(Fig. 3A and B). These effects were similar to those of the PI3K inhibitor and the
Akt inhibitor. A cAMP analog, dibutyryl cAMP, also decreased leptin secretion
(Fig. 3C). In contrast to cilostazol, the insulin upregulation of leptin mRNA was
abrogated by dibutyryl cAMP (Fig. 3D).
3.4. Epinephrine decreases leptin secretion and mRNA
Since cAMP acts as the second messenger in the signal transmission of multiple
hormones including epinephrine, we next examined the effect of epinephrine on
leptin secretion and expression. Epinephrine dose-dependently decreased leptin
secretion from adipocytes cultured with glucose-free medium (Fig. 4A).
Concomitantly, the mRNA expression of leptin was reduced by epinephrine in a
dose-dependent manner (Fig. 4B). The epinephrine suppression of leptin secretion
was not improved with prazosin, an alpha1-adrenergic receptor antagonist, but
significantly ameliorated with propranolol, a nonselective beta-adrenergic receptor
antagonist (Fig. 4C). In harmony, propranolol partially, though statistically
insignificant, recovered the epinephrine suppression of leptin mRNA (Fig. 4D).
Epinephrine clearly inhibited insulin-induced leptin hypersecretion (Fig. 4E).
[(Fig._2)TD$FIG]
Fig. 2. Regulation of leptin secretion and mRNA levels by the insulin signaling pathway in 3T3-L1
adipocytes under glucose depletion. 3T3-L1 adipocytes were incubated for 8 h in glucose-free DMEM
containing insulin (0.5 μM) with or without the PI3K inhibitor BEZ-235 (0.1, 1, 10 μM) and the Akt
inhibitor MK-2206 (0.1, 1, 10 μM). (A and B) Effects of BEZ-235, (C) wortmannin, and (D and E) MK-
2206 on leptin secretion and mRNA expression. (F) MTS assay after 24 h-incubation. *p < 0.05, **p <
0.01, and ***p < 0.001. n.s., not significant. Data are expressed as means ± SE.
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Unexpectedly, an adenylate cyclase inhibitor, SQ22536, failed to significantly
attenuate the epinephrine suppression of leptin secretion (Fig. 4F).
3.5. Regulation of leptin secretion and mRNA expression by
insulin signaling in the presence of glucose
We also examined the regulation of leptin secretion and mRNA expression by
insulin signaling in 3T3-L1 adipocytes under normal glucose levels. Insulin-
induced leptin secretion was blocked by both the PI3K inhibitor and the Akt
inhibitor (Fig. 5A). In contrast to the glucose-free condition, leptin mRNA
expression was decreased by the PI3K and Akt inhibitors in the normal glucose
condition (Fig. 5B), despite the fact that insulin did not augment leptin expression
in the presence of glucose. A PDE3B inhibitor, cilostazol, failed to suppress
insulin-induced leptin secretion in the presence of glucose (Fig. 5C). Both leptin
secretion and mRNA levels were also reduced by dibutyryl cAMP in the presence
[(Fig._3)TD$FIG]
Fig. 3. Effects of the PDE3B inhibitor cilostazol (A and B) or a cyclic AMP analog (C and D) on
insulin-induced leptin secretion and mRNA levels in 3T3-L1 adipocytes under glucose-free conditions.
3T3-L1 adipocytes were incubated for 8 h in glucose-free DMEM with each substance at the indicated
concentrations. *p < 0.05, ***p < 0.001. n.s., not significant. Data are expressed as means ± SE.
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of glucose, as was observed under glucose depletion (Fig. 5C and D). Epinephrine
showed similar results as the cAMP analog did (Fig. 5E and F).
4. Discussion
In this study, we found that insulin increased leptin secretion from 3T3-L1
adipocytes under the complete depletion of glucose. The glucose level in the
medium did not affect leptin secretion after insulin stimulation, while basal leptin
secretion was elevated along with increasing glucose levels. Our results also
showed that inhibitors for PI3K and Akt were able to suppress the insulin
[(Fig._4)TD$FIG]
Fig. 4. Effect of epinephrine on leptin secretion and mRNA levels under glucose depletion. 3T3-L1
adipocytes were incubated for 8 h in glucose-free DMEM with epinephrine, an alpha1-adrenergic
receptor antagonist (prazosin), and a nonselective beta-adrenergic receptor antagonist (propranolol). (A
and B) Effects of epinephrine on leptin secretion and mRNA levels. (C and D) Effects of prazosin and
propranolol on epinepfrine-induced suppression of leptin secretion and mRNA levels. (E) Epinephrine
suppresses insulin effects on leptin secretion. (F) Effect of an adenylate cyclase inhibitor, SQ22536, on
the epinephrine suppression of leptin. *p < 0.05, **p < 0.01, and ***p < 0.001. n.s., not significant.
Data are expressed as means ± SE.
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stimulation of leptin secretion in glucose-free media. These data, consistent with
previous studies [15, 16, 17], indicate that insulin alone enhances leptin secretion
and accelerated glucose uptake and catabolism are unlikely to be essential to the
insulin effects on leptin. It was previously reported that insulin had no effect on
leptin secretion from primary adipocytes under glucose-free condition [22],
although that study was performed using the Krebs-Ringer buffer deprived of not
only glucose but also of amino acids and other nutrients, differing from our
glucose-free DMEM containing various amino acids. Indeed, the addition of amino
acids, but not glucose, recovered insulin action on leptin in the study [22].
We also demonstrated that a PDE3B inhibitor and a cAMP analog abrogated
insulin stimulation of leptin secretion under glucose depletion. In addition,
epinephrine markedly inhibited leptin secretion from adipocytes, probably through
β-adrenergic receptors. Previous studies performed with normal glucose levels
have shown that insulin and β-adrenergic agonists affect leptin secretion via
cAMP-dependent mechanisms [7, 19]. These data strongly suggest that cAMP
reduction as a result of augmented insulin signaling plays a central role in the
insulin-induced leptin secretion, independent of glucose metabolism.
[(Fig._5)TD$FIG]
Fig. 5. Effects of the PI3K inhibitor BEZ-235 and the Akt inhibitor MK-2206 (A and B), cilostazol (C),
cAMP (D and E), and epinephrine (F and G) on leptin secretion and mRNA levels in 3T3-L1 adipocytes
in the presence of 5.5 mM glucose with insulin. 3T3-L1 adipocytes were incubated for 8 h in DMEM
containing 5 mM glucose with a combination of the substances at the indicated concentrations.*p <
0.05, **p < 0.01 and ***p < 0.001. n.s., not significant.
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On the contrary, we found that basal leptin secretion without insulin stimulation
was associated with glucose levels in the media. A previous study reported that 2-
deoxy-D-glucose (2DG), a glucose analog that inhibits glucose catabolism,
attenuated glucose-induced leptin secretion [27]. In addition, pyruvate and
gluconeogenic amino acids potently stimulated leptin secretion in the absence of
insulin or ambient glucose [22]. These data indicate that glucose metabolism is
also involved in leptin secretion. Because the glucose-induced leptin secretion was
not observed under insulin stimulation, there seems to be an interaction between
glucose and insulin. Glucose is known to inhibit adenylate cyclase and
subsequently decreases intracellular cAMP levels [28, 29]. This effect likely
intertwines the insulin suppression of cAMP and thus may explain why glucose
and insulin do not show an additional effect on leptin secretion. Our data that a
PDE3B inhibitor lost suppressive effects on leptin secretion in the presence of
glucose could be relevant to the cAMP levels.
It should be noted that there is an overt discrepancy between the secretion and
mRNA levels of leptin in the response to insulin, glucose and inhibitors for the
PI3K-Akt pathway. In contrast to secretion, leptin mRNA levels tended to be
suppressed in the presence of glucose and the insulin-induced mRNA increase was
abolished by glucose. Inhibitors for PI3K-Akt signaling suppressed insulin-induced
leptin secretion, but not leptin mRNA in a glucose-free condition. Intriguingly, our
data showed that the inhibitors for PI3K and Akt suppressed leptin mRNA in the
presence of glucose, despite the fact that insulin failed to augment leptin mRNA
It has been reported that leptin is stored mainly as a membrane-bound form in
adipocytes and insulin enhances leptin secretion, but not leptin synthesis [30]. In
addition, insulin was reported to increase leptin synthesis without affecting its
mRNA levels [31]. These findings along with present data indicate that leptin
secretion is regulated by mechanisms independent of its mRNA levels.
Although detailed mechanisms for leptin secretion and synthesis remain to be
elucidated, the AMPK-mTOR system, a mechanism related to intracellular energy
status, may affect insulin-induced leptin synthesis (Fig. 6). Insulin stimulates
mTORC1, which possibly enhances the translation of leptin mRNA [32] and
regulates promoter activity for leptin genes [33]. These observations appear
relevant to the present results that insulin lost its stimulatory effects on leptin
mRNA under glucose-sufficient condition, where mTORC1 is already activated as
a result of suppressed AMPK [34]. In addition, the low level of cAMP in the
presence of glucose may cause AMPK inactivation, because cAMP has been
reported to activate AMPK in adipocytes [35]. In harmony, our data clearly
showed that the direct addition of a cAMP analog, in contrast to insulin of which
effect on cAMP is likely influenced by glucose, suppressed leptin mRNA levels
regardless of whether glucose is present. However, this AMPK-mTOR hypothesis
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may be vulnerable because our data showed that basal leptin mRNA levels were
not increased but rather decreased by the presence of glucose.
It also remains to be clarified why the inhibitors for PI3K and Akt suppressed
leptin mRNA only in the presence of glucose, where insulin failed to augment
leptin mRNA. Although the reason is unknown, the PI3K-Akt pathway mediates
signals from multiple receptors other than insulin and thus hypothetically affects
leptin mRNA levels independent of insulin action
Our data have shown that cAMP rather than glucose metabolism plays a primary
role in the insulin effect on leptin, indicating that hormones activating adenylate
cyclase may directly suppress the insulin action on leptin. Indeed epinephrine
strongly suppressed the insulin action on leptin in the present study regardless
whether or not glucose is present, although it has to be explained why an adenylate
cyclase inhibitor failed to ameliorate the epinephrine effect. Because epinephrine
along with glucocorticoids and glucagon has been reported to increase in obesity
and metabolic syndrome [36, 37, 38], these adenylate cyclase stimulating
hormones possibly diminish the leptin elevation in obesity and exacerbate the
pathophysiology of the disease.
It should be noted that the interpretation of present results is limited because this
study lacks in vivo experiments and 3T3-L1 adipocytes, though most established
cell lines, have been reported to show some different characteristics from primary
[(Fig._6)TD$FIG]
Fig. 6. Hypothetical explanation for insulin-glucose interaction in leptin regulation in adipocytes.
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adipocytes, including low leptin secretion [5]. The detailed mechanisms of leptin
regulation such as trafficking, transcription, translation and degradation also
remain to be elucidated.
5. Conclusion
Insulin regulates leptin secretion and mRNA expression in adipocytes via cAMP.
Glucose metabolism is not essential for the insulin effects but may indirectly
influence the insulin effects, speculatively through altered cAMP levels. Given the
importance of leptin in the pathogenesis of obesity and related diseases, detailed
regulatory mechanisms of the hormone need further clarification.
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